ARINA-1 is a nebulized therapy with the ability to restore lung health in patients with diseases that impact their airways. It is currently being developed for use in patients with non-CF bronchiectasis, lung transplant and COPD. Renovion plans to initiate clinical trials in the United States in 2021.
Given its strong track record for safety and efficacy, as well as its unique mechanism of action, ARINA-1 can significantly improve the lives of patients with often debilitating chronic diseases that lead to early death.
IMPROVING LUNG HEALTH
ARINA-1 is a first-in-class therapy that addresses deficiencies in the innate immune system that occur in chronic inflammatory airway diseases, such as non-CF bronchiectasis, COPD, and lung transplant.
In these diseases, thick mucus often accumulates in the lungs. The mucus cannot be effectively cleared out of the airways, which leads to mucus plugging and difficulty breathing. Mucus plugging and excessive mucus production leads to pathological inflammation, which can exacerbate mucus production and plugging. This vicious cycle of mucus and inflammation in the airway damages the airway and makes it more susceptible to infection.
ARINA-1 can break this cycle. ARINA-1 restores critical components of the innate immune system to enhance mucus clearance and decrease pathological inflammation. By restoring these defenses, ARINA-1 can improve lung health by maintaining a barrier from not only inflammation within the lungs, but also environmental stresses that can cause inflammation and infection and result in clinical decline.